... for the treatment of PCA, we evaluated the efficacy of intralesional administration of the Sirt3 activator Honokiol (HK) and the NADPH oxidase inhibitor Dibenzolium (DIB). Methods: We used a well-established transgenic adenocarcinoma mouse prostate (TRAMP-C2) model of hormone-independent PCA. MTS assay, apoptosis...

.... These 2 CDK9 inhibitors induced apoptosis in HCC cells and reduced the expression of antiapoptotic proteins such as myeloid cell leukemia-1 and survivin. In the xenograft studies, mice receiving either CDK9 inhibitor exhibited significantly slower tumor growth than did the mice receiving vehicles...

... loss) and U373VR (MGMT upregulation). Analogs 1 and 2 inhibited MMR-deficient colorectal carcinoma cell growth (irrespective of p53); G2/M cell cycle arrest preceded apoptosis. GH2AX foci inferred the generation of DNA double-strand breaks by analogs 1 and 2 . Acridine orange-stained vesicles...

... alternatives of treatment. X-linked inhibitor of apoptosis (XIAP) is highly expressed in gliomas and, due to its inhibition of caspases, can participate in resistance to therapy. Here we test the sensitization of glioma cells with XIAP gene knockdown (KD) to drugs used in chemotherapy. Methods: We silenced...

...-induced apoptosis. The processing of MAGE-A4 was inhibited by the proteasome inhibitors MG115, MG132, lactacystin and epoxamicin. MAGE-A4 was coimmunoprecipitated with the S6 proteasomal ATPase, and present in the fractions containing the proteasome during glycerol gradient centrifugation. Consistent...

... stimulators, provoke the release of stimulators bound to the surrounding extracellular matrix and induce macrophages to secrete angiogenesis stimulators, thereby promoting angiogenesis. Metastasis dormancy is characterized by a balance between cell proliferation and apoptosis and is thought to be controlled...

... with glioma cells or human umbilical vein endothelial cells (HUVECs) at varying ratios for ganciclovir in vitro. Cell proliferation was evaluated by MTT assay, and apoptosis was examined by annexin-V and phosphatidylserine (propidium iodide) staining. EPCs were injected via tail vein into nude mice bearing...

... targeting VEGF significantly silenced VEGF expression in SKOV3 ovarian cancer cells, confirmed by RT-PCR and ELISA assays (p < 0.05). In vivo, the shRNA reduced tumor weight by ∼60.3% compared with control groups (p < 0.05), accompanied with angiogenesis inhibition (p < 0.01) and apoptosis...

...Yong Wang; Lingdi Ma; Shizhong Wang; Yongyi Bao; Cheng Ni; Naifu Guan; Jianzhong Zhao; Xiaolong Fan Adenoviral vector-mediated transfer of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be a powerful approach to lung cancer therapy. However, the efficiency of adenoviral vector...

... and immunoblotting in human ONB cell lines. The impact of the treatment with cyclopamine (a selective inhibitor of the Shh pathway) and/or exogenous Shh on ONB cell proliferation, cycle and apoptosis was examined by MTT, soft agar colony formation and flow cytometry assays, respectively. The influence of Shh...

... but not in the KF-1 cells. The pattern of cell death in HMG cells was considered to be apoptosis, but that of KF-1 cells necrosis. These findings showed the different mechanisms of antitumor effect of cisplatin on human ovarian carcinoma cell lines, including cell kinetics and pattern of cell death. 30 6 2009...

... and bcl-2 expression was immuno-histochemically studied on paraffin-embedded sections from 70 patients with STS in the extremities and trunk. In addition, the degree of apoptosis was examined by in situ end-labeling. Histologic diagnoses in these cases were malignant fibrous histiocytoma in 29 cases...

... factor in the growth of HCC < 5 cm. 30 6 2009 Hepatocellular carcinoma Transforming growth factors Growth kinetics Apoptosis Proliferating cell nuclear antigen Lewis Y antigen © 1997 S. Karger AG, Basel 1997 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved...

... whether the suppression of the PI3K catalytic subunit p110αinhibits the growth of ovarian cancer cells in vitro and in vivo. Methods: The short hairpin RNA (shRNA) was used to knock down the expression of p110α in SKOV3 human ovarian cancer cells. The effects of shRNA on cell viability and apoptosis...

... growth in a hypoxic state compared to cells in a normoxic condition. This suppression was due to the induction of apoptosis through activating mitochondrial apoptotic signaling cascades. This study demonstrates that hypoxia stimulates HCC cellular growth through HK II induction, and its inhibition...

... effect of each preparation was different, but IFN-β expressed the strongest effects in vitro. Induction of an inhibition of cell cycle progression at the G 1 , S or G 2 /M phase with or without apoptosis was the mechanism of action of IFN. IFN preparations induced a dose-dependent decrease in tumor...

... ovarian cancer in vitro and in vivo. Methods: Ovarian cancer SKOV3 cells were transfected with hPNAS-4-plasmid, and cell proliferation was evaluated by MTT assay; apoptosis was examined by DNA ladder, Hoechst33258 staining and flow-cytometric assays. Nude mice bearing ovarian cancers were treated...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Rectal neoplasm Apoptosis Caspase-8 Caspase-10 Immunohistochemistry RT-PCR Colorectal cancer is one of the common gastrointestinal...

... 1 RNA silencing Cell cycle Apoptosis Esophageal cancer is the third most common cancer of the digestive tract and the sixth leading cause of cancer-related death worldwide with approximately 400,000 new cases diagnosed annually [ 1 ]. Despite recent refinement of various therapeutic...

... to treatments, both individually and in combination. Using this model, our laboratory has previously demonstrated that the growth of several human adenocarcinomas can be inhibited by Apo2L/TRAIL. Apo2L/TRAIL triggers apoptosis in many types of tumor cells, and when combined with various chemotherapeutic agents...